Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 02-03 15:01:47 EST

1.14

-0.09

-7.60%

High1.23	Low1.10	Vol1.98M
Open1.23	D1 Closing1.23	Amplitude10.57%
Mkt Cap131.10M	Tradable Cap114.56M	Total Shares115.35M
T/O2.28M	T/O Rate1.97%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":1.1365,"timestamp":1770148898263,"preClose":1.23,"halted":0,"volume":1983009,"delay":0,"changeRate":-0.07601626016260156,"floatShares":100797117,"shares":115352289,"eps":-1.317989,"marketStatus":"Trading","change":-0.0935,"latestTime":"02-03 15:01:47 EST","open":1.23,"high":1.23,"low":1.1,"amount":2277563.5704528,"amplitude":0.105691,"askPrice":1.14,"askSize":4465,"bidPrice":1.13,"bidSize":9157,"shortable":0,"etf":0,"ttmEps":-1.317989,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770152400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":1.23,"preHourTrading":{"tag":"盘前","latestPrice":1.25,"preClose":1.23,"latestTime":"08:30 EST","volume":4234,"amount":5252.141511999999,"timestamp":1770125437858,"change":0.02,"changeRate":0.01626,"amplitude":0.023171},"postHourTrading":{"tag":"盘后","latestPrice":1.22,"preClose":1.23,"latestTime":"19:09 EST","volume":7722,"amount":9467.6366,"timestamp":1770077381045,"change":-0.01,"changeRate":-0.00813,"amplitude":0.00813},"volumeRatio":1.424913,"impliedVol":0.4033,"impliedVolPercentile":0.0757},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2604408499","title":"Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year","url":"https://stock-news.laohu8.com/highlight/detail?id=2604408499","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604408499?lang=en_us&edition=fundamental","pubTime":"2026-01-17 20:45","pubTimestamp":1768653917,"startTime":"0","endTime":"0","summary":"Key Insights Significantly high institutional ownership implies Fate Therapeutics' stock price is sensitive to their...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/great-week-for-fate-therapeutics-inc-nasdaqfate-institutiona-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fate/fate-therapeutics/news/great-week-for-fate-therapeutics-inc-nasdaqfate-institutiona-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SQQQ","FATE","QID","QYLD","PSQ","QLD","TSYW.SI","QQQJ","USJW.SI","MNQmain","TQQQ",".IXIC","BK4139","NVIW.SI","QYLG","USAW.SI","NQmain","QQQM","QQQE","GPIQ","QQQY"],"gpt_icon":1},{"id":"2603575913","title":"Top Fate Therapeutics Insider Makes a Quiet Move That Investors Can’t Ignore","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603575913?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:01","pubTimestamp":1768269691,"startTime":"0","endTime":"0","summary":"New insider activity at Fate Therapeutics ( ($FATE) ) has taken place on January 12, 2026. Chief Legal and Compliance Officer Cindy Tahl has recent...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-fate-therapeutics-insider-makes-a-quiet-move-that-investors-cant-ignore-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-fate-therapeutics-insider-makes-a-quiet-move-that-investors-cant-ignore-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","ISBC","FATE","BK4139"],"gpt_icon":0},{"id":"2601378588","title":"Fate Therapeutics Grants Stock Options and RSUs to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2601378588","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601378588?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647123,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc. has granted non-qualified stock options to one newly hired non-executive employee for the purchase of 48,000 shares at an exercise price of $0.98 per share, reflecting the closing price on December 31, 2025. Additionally, restricted stock units  totaling 79,400 shares were awarded to four newly hired non-executive employees. The stock options vest over four years, with 25% vesting after one year and the remainder vesting in equal monthly installments over the following three years. The RSUs also vest over four years, with 25% vesting on each anniversary of the grant date. Vesting is contingent on continued employment with the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL2MFqVb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","FATE","IE00B64PRP62.GBP","SG9999014013.SGD","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","SG9999014005.SGD","BK4588","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2601997837","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601997837","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601997837?lang=en_us&edition=fundamental","pubTime":"2026-01-06 05:05","pubTimestamp":1767647100,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Jan.  05, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/05/3213196/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2589535393","title":"Fate Therapeutics Reports Promising Phase 1 Results for Off-the-Shelf CAR T-Cell Therapy in Lupus","url":"https://stock-news.laohu8.com/highlight/detail?id=2589535393","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589535393?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:00","pubTimestamp":1765198826,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc. has presented updated clinical data from its ongoing Phase 1 trial evaluating FT819, an off-the-shelf iPSC-derived CAR T-cell product candidate, in patients with systemic lupus erythematosus . The data, presented at the 2025 American Society of Hematology  Annual Meeting & Exposition, include results from 13 enrolled patients-12 with SLE and one with systemic sclerosis. The updated findings show sustained clinical responses, durable B-cell depletion, and a favorable safety profile without the need for intensive-conditioning chemotherapy. Fate Therapeutics also announced preclinical advances in its next-generation off-the-shelf CAR T-cell programs, FT836 and FT839, targeting hematologic malignancies and autoimmune diseases. The company is preparing for a registrational study of FT819 in 2026 and is in discussions with the U.S. FDA under the Regenerative Medicine Advanced Therapy  designation.Disclaimer: This news brief was created by Public Technologies  using gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL3Qwpv3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","BK4588","FATE","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD","NDAQ","BK4112","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4139","SG9999014039.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2586473258","title":"Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586473258","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586473258?lang=en_us&edition=fundamental","pubTime":"2025-11-25 21:00","pubTimestamp":1764075600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  25, 2025  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/25/3194267/24675/en/Fate-Therapeutics-to-Present-at-Piper-Sandler-37th-Annual-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","XBI","LABU","BK4137","LU0029874061.USD","BK4588","HCSG","BK4581","BK4585","FATE","BK4139","XLV"],"gpt_icon":0},{"id":"2584047607","title":"Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2584047607","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584047607?lang=en_us&edition=fundamental","pubTime":"2025-11-18 11:55","pubTimestamp":1763438113,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a breakdown of the information Fate Therapeutics Inc presented to its inves...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-reports-q3-loss-amid-restructuring-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-reports-q3-loss-amid-restructuring-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2584617074","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584617074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584617074?lang=en_us&edition=fundamental","pubTime":"2025-11-17 15:30","pubTimestamp":1763364624,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), ALX On...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-60-degrees-pharmaceuticals-inc-sxtp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-fate-therapeutics-fate-alx-oncology-holdings-alxo-and-60-degrees-pharmaceuticals-inc-sxtp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","LU0029874061.USD","ALXO","LU0128526141.USD","BK4585","ALX","FATE","SXTP","BK4231","HCSG","XBI","BK4139","LABU","BK4007","XLV","BK4080","BK4588"],"gpt_icon":0},{"id":"2583665269","title":"Navigating Data Privacy Challenges: Fate Therapeutics’ Battle with Regulatory Compliance and Business Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2583665269","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583665269?lang=en_us&edition=fundamental","pubTime":"2025-11-16 14:00","pubTimestamp":1763272841,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc (FATE) has disclosed a new risk, in the Environmental / Social category. Fate Therapeutics Inc. faces significant business ri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/navigating-data-privacy-challenges-fate-therapeutics-battle-with-regulatory-compliance-and-business-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/navigating-data-privacy-challenges-fate-therapeutics-battle-with-regulatory-compliance-and-business-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2583656244","title":"Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2583656244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583656244?lang=en_us&edition=fundamental","pubTime":"2025-11-16 01:35","pubTimestamp":1763228125,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Hold rating on Fate Therapeutics, with a price target of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-receives-a-hold-from-bank-of-america-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-receives-a-hold-from-bank-of-america-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BAC","IE00B19Z3581.USD","LU0971096721.USD","LU0203345920.USD","LU0980610538.SGD","LU1668664300.SGD","BK4504","LU1363072403.SGD","FATE","IE00B7SZLL34.SGD","LU0128525689.USD","LU0208291251.USD","LU0648000940.SGD","IE00BLSP4452.SGD","LU0648001328.SGD","BK4585","LU1718418525.SGD","LU1880398554.USD","LU0640476718.USD","BK4207","LU1496350171.SGD","IE00BKVL7J92.USD","LU1267930227.SGD","LU2129689431.USD","LU0170899867.USD","LU0321505439.SGD","LU0306807586.USD","LU1074936037.SGD","LU0256863902.USD","LU0477156953.USD","LU2265009873.SGD","LU0203347892.USD","BK4553","LU0070302665.USD","LU2129689605.HKD","LU1366192091.USD","LU0320765646.SGD","LU1280957306.USD","LU1894683264.USD","LU0314106906.USD","LU0234572021.USD","LU0130103400.USD","LU1201861165.SGD","LU1496350502.SGD","IE00BZ1G4Q59.USD","LU0683600562.USD","IE0002270589.USD","LU1506573853.SGD","LU0787776722.HKD"],"gpt_icon":0},{"id":"2583516290","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Indaptus Therapeutics (INDP) and Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583516290","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583516290?lang=en_us&edition=fundamental","pubTime":"2025-11-14 03:40","pubTimestamp":1763062814,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Indaptus Therapeutics (INDP – Research Report) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-indaptus-therapeutics-indp-and-fate-therapeutics-fate-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-indaptus-therapeutics-indp-and-fate-therapeutics-fate-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XLV","BK4137","BK4139","HCSG","LU0029874061.USD","FATE","BK4585","INDP","BK4581","LABU","XBI","BK4588"],"gpt_icon":0},{"id":"2583941445","title":"Fate Therapeutics: Balancing Potential and Uncertainty with FT819’s Promise in Autoimmune Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583941445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583941445?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:25","pubTimestamp":1763047532,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tara Bancroft has maintained their neutral stance on FATE stock, giving a Hold rating on November 6. Tara Bancroft’s rating is bas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/fate-therapeutics-balancing-potential-and-uncertainty-with-ft819s-promise-in-autoimmune-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/fate-therapeutics-balancing-potential-and-uncertainty-with-ft819s-promise-in-autoimmune-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2583934495","title":"Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583934495","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583934495?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:41","pubTimestamp":1763041282,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of $(0.40) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48832403/fate-therapeutics-q3-eps-0-27-beats-0-29-estimate-sales-1-741m-beat-1-535m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"gpt_icon":0},{"id":"2583593647","title":"Fate Therapeutics reports Q3 EPS (27c), consensus (28c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593647?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:35","pubTimestamp":1763040950,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $1.741M, consensus $1.68M. “The potentially transformative impact of FT819 in lupus is at an inflection point as we enter the fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-reports-q3-eps-27c-consensus-28c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-reports-q3-eps-27c-consensus-28c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"gpt_icon":0},{"id":"2583350593","title":"Fate Therapeutics reports third quarter 2025 revenue of $1.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583350593","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583350593?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040628,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc. reported total revenue of $1.7 million for the third quarter of 2025, primarily from preclinical development activities under its collaboration with Ono Pharmaceutical. Total operating expenses for the quarter were $36.5 million, including $25.8 million in research and development and $10.6 million in general and administrative expenses. Cash, cash equivalents, and investments totaled $225.7 million as of September 30, 2025. The company projected its operating runway through the end of 2027 with $226 million in available funds. Key business developments included authorization to activate ex-US clinical trial sites for FT819, the treatment of the first systemic sclerosis patient in a Phase 1 study of FT819, and the first patient treated with FT836 in a solid tumor study. Kamal Adawi was appointed Chief Financial Officer during the period. As of September 30, 2025, the company had 115.3 million common shares outstanding, 3.9 million pre-funded warrants, and 2.8 mil","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7KwZ1K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","FATE","BK4585","LU2210149790.SGD","BK4112","BK4588"],"gpt_icon":0},{"id":"2583593301","title":"Fate Therapeutics Q3 Net Income USD -32.25 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593301","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593301?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXC323E0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FATE","BK4139"],"gpt_icon":0},{"id":"2583966185","title":"Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583966185","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583966185?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:30","pubTimestamp":1763040600,"startTime":"0","endTime":"0","summary":"Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187342/24675/en/Fate-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","LU2463526074.USD","BK4081","CRC","BK4233","IE00B19Z4B17.USD","BK4230","BK4006","BK4156","LU0963586101.USD","LU0266512127.USD","ASH","BK4213","BK4109","UK","BK4110","IE00B66KJ199.SGD","SLE","LU2065731478.USD","BK4139","FATE","BK4528","BK4187","ACR","EMA","IIM","IE0031619046.USD","BK4077","BK4205","IE00B7SZL793.SGD","CRS","CAR","LU0456854461.SGD"],"gpt_icon":0},{"id":"2581851558","title":"Fate Therapeutics Inc  expected to post a loss of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581851558","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581851558?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:41","pubTimestamp":1762522867,"startTime":"0","endTime":"0","summary":"Fate Therapeutics Inc  expected to post a loss of29cents a share - Earnings Preview Fate Therapeutics Inc FATE.OQ FATE.O is expected to  show a fall in quarterly revenue when it reports  results on No","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ1PQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"gpt_icon":0},{"id":"2581876967","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581876967","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581876967?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290060,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Nov.  04, 2025  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180811/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIW.SI","FATE","USAW.SI","MNQmain","USJW.SI","PSQ","QLD","TQQQ",".IXIC","NQmain","QID","SQQQ","TSYW.SI","BK4139"],"gpt_icon":1},{"id":"2580514413","title":"Fate Therapeutics Shares Rise After HC Wainwright Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2580514413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580514413?lang=en_us&edition=fundamental","pubTime":"2025-11-01 03:00","pubTimestamp":1761937229,"startTime":"0","endTime":"0","summary":"Fate Therapeutics (FATE) shares rise 5% in recent Friday trading after HC Wainwright upgraded the stock to buy from neutral with a price target of $5.Inraday volume topped 1.12 million shares, compared with the daily average of almost 2.1 million.Price: 1.36, Change: +0.07, Percent Change: +5.04","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FATE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.247},{"period":"3month","weight":0.0336},{"period":"6month","weight":0.1827},{"period":"1year","weight":-0.0538},{"period":"ytd","weight":0.2518}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.061929},{"month":3,"riseRate":0.5,"avgChangeRate":-0.006528},{"month":4,"riseRate":0.583333,"avgChangeRate":0.001011},{"month":5,"riseRate":0.416667,"avgChangeRate":-0.020051},{"month":6,"riseRate":0.5,"avgChangeRate":0.003206},{"month":7,"riseRate":0.416667,"avgChangeRate":0.050198},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}